Visterra Makes Debut at ICAAC with Flu Antibody, Partnership

The typical way to identify a broadly neutralizing antibody is to screen B cells for one, and then look for an epitope that can induce its production. Cambridge, Mass.-based start-up Visterra Inc. used a very different approach to come up with its VIS410, an antibody that is capable of neutralizing all strains of influenza A that the company has tested.